Pharmacological treatment of hyperthyroidism during lactation: review of the literature and novel data

Pediatric Endocrinology Reviews

Volumn 8, Issue 1, 2010, Pages 25-33

  Karras, Spiros ^a   Tzotzas, Themistoklis ^a   Kaltsas, Themistoklis ^a   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

Antithyroid drugs; Breastfeeding; Carbimazole; Hyperthyroidism; Lactation; Methimazole; Pregnancy; Propylthiouracil

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE; THIOURACIL; THIOUREA;

BREAST FEEDING; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MILK LEVEL; DRUG PROTEIN BINDING; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HUMAN; HYPERTHYROIDISM; INTELLIGENCE QUOTIENT; LACTATION; LIVER DYSFUNCTION; PHYSICAL DEVELOPMENT; REVIEW; THYROID FUNCTION; THYROTOXICOSIS;

ADULT; ANTITHYROID AGENTS; BREAST FEEDING; CARBIMAZOLE; CHILD DEVELOPMENT; FEMALE; HUMANS; HYPERTHYROIDISM; INFANT; LACTATION; METHIMAZOLE; MILK, HUMAN; MOTHERS; PROPYLTHIOURACIL;

EID: 78650274525     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler 1. Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ, Eidelman AI; American Academy of Pediatrics Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506
2. World Health Organization. Global strategy for infant and young child feeding. Geneva, Switzerland: WHO, 2002
3. Chen A, Rogan WJ. Breastfeeding and the risk of postneonatal death in the United States. Pediatrics 2004;113:e435-e439
4. Schanler RJ. Evaluation of the evidence to support current recommendations to meet the needs of premature infants: the role of human milk. Am J Clin Nutr 2007;85:625S-628S
5. Mayer-Davis EJ, Dabelea D, Lamichhane AP, D'Agostino RB Jr, Liese AD, Thomas J, McKeown RE, Hamman RF. Breast-feeding and type 2 diabetes in the youth of three ethnic groups: the search for diabetes in youth case-control study. Diabetes Care 2008;31:470-475
6. Plagemann A, Harder T. Breast feeding and the risk of obesity and related metabolic diseases in the child. Metab Syndr Relat Disord 2005;3:222-232 (Pubitemid 41601240)
7. Michaelsen KF, Lauritzen L, Mortensen EL. Effects of breast-feeding on cognitive function. Adv Exp Med Biol 2009;639:199-215
8. Martin RM, Middleton N, Gunnell D, Owen CG, Smith GD. Breastfeeding and cancer: the Boyd Orr cohort and a systematic review with meta-analysis. J Natl Cancer Inst 2005;97:1446-1457 (Pubitemid 41520080)
9. Jordan SJ, Siskind V, C Green A, Whiteman DC, Webb PM. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 2010;21:109-116
10. Lopez JM, Gonzalez G, Reyes V, Campino C, Diaz S. Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporos Int 1996;6:153-159
11. World Health Organization and United Nations Children's Fund. Protecting, promoting and supporting breast-feeding: the special role of maternity services. Geneva, Switzerland: WHO and UNICEF 1989;13-18
12. Institute of Medicine, Committee on Nutritional Status during Pregnancy and Lactation. Nutrition during lactation. Washington, DC: National Academy Press, 1991:24-25, 161-171, 197-200
13. James DC, Dobson B; American Dietetic Association. Position of the American Dietetic Association: promoting and supporting breastfeeding. J Am Diet Assoc 2005;105:810-818
14. Dyson L, Renfrew MJ, McFadden A, McCormick F, Herbert G, Thomas J. Policy and public health recommendations to promote the initiation and duration of breast-feeding in developed country settings. Public Health Nutr 2010;13:137-144
15. Pechlivani F, Vassilakou T, Sarafidou J, Zachou T, Anastasiou CA, Sidossis LS. Prevalence and determinants of exclusive breastfeeding during hospital stay in the area of Athens, Greece. Acta Paediatr 2005;94:928-934
16. Hale TW, Ilett KF. Drug therapy and breastfeeding. From theory to clinical practice. 1st ed. London: The Parthenon Publishing Group, 2002;1-94
17. Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000;343:118
18. Amino N, Tada H, Hidaka Y. The spectrum of postpartum thyroid dysfunction: diagnosis, management, and long-term prognosis. Endocr Pract 1996;2:406-410
19. Benhaim Rochester D, Davies TF. Increased risk of Graves' disease after pregnancy. Thyroid 2005;15:1287-1290
20. Rotondi M, Pirali B, Lodigiani S, Bray S, Leporati P, Chytiris S, Balzano S, Magri F, Chiovato L. Post partum period and the onset of Graves' disease: an overestimated risk factor. Eur J Endocrinol 2008;159:161-165
21. Hale TW. Medications and mothers' milk. 10th ed. Amarillo, TX: Pharmasoft Publishing, 2000
22. Wilson JT, Brown RD, Cherek DR, Dailey JW, Hilman B, Jobe PC, Manno BR, Manno JE, Redetzki HM, Stewart JJ. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980;5:1-66
23. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmakokinet 1988;14:217-240
24. Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ. Interactions between cimatidine, nitrofurantoin and probenecid active transport into rat milk. J Pharmacol Exp Ther 2001;296:175-180
25. Howard CR, Lawrence RA. Drugs and breastfeeding. Clin Perinatol 1999;26:447-478
26. Auerbach KG. Breastfeeding and maternal medication use. J Obstet Gynecol Neonatal Nurs 1999;28:554-563
27. Besunder JB, Reed MD, Blumer JL. Principles of drug biodispodition in the neonate; a critical evaluation of the pharmacokineticpharmakodynamic interface. Clin Pharmakokinet 1988;14:261-286
28. Begg EJ, Atkinson HC, Duffull SB. Prospective evaluation of a model for the prediction of milk: plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmacol 1992;33:501-505
29. Fleishaker JC, McNamara PJ. In vivo evaluation in the lactating rabbit of a model for xenobiotic distribution into breastmilk. J Pharmacol Exp Ther 1988;244:919-924
30. Notarianni LJ, Belk D, Aird SA, Bennett PN. An in vitro technique for the rapid determination of drug entry into breast milk. Br J Clin Pharmacol 1995;40:333-337
31. Ito S, Koren G. A novel index for expressing exposure of the infant to drug in breast milk. Br J Clin Pharmacol 1994;38:99-102 (Pubitemid 24247749)
32. Hale TW, Ilett KF. Drug therapy and breastfeeding: from theory to clinical practice. New York: The Parthenon Publishing Group, 2002
33. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003;88:3474-3481
34. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-917
35. Janson R, Dahlberg PA, Lindstrom B. Comparative bioavaibility of carbimazole and methimazole. Int J Clin Pharamcol Ther Toxicol 1983;21:505-510
36. Ringhand HP, Ritschel WA, Meyer MC, Straughn AB, Cabana BE. Bioavailability of propylthiouracil in humans. J Pharm Sci 1983;72:1409-1412
37. Zatón A, Martinez A, Manuel de Gandarias J. The binding of thiouelene compounds to human serum albumin. Biochem Pharmacol 1988;37:3127-3131
38. Farwell AP, Braverman LE. Thyroid and antithyroid drugs. In: Hardman JG, Limbird LE, Goodman Gilman A, eds. Goodmans and Gilmans: The pharmacological basis of therapeutics. 10th ed, USA: Mc Graw Hill, 2001;1563-1596
39. Skellern GG, Knight BI, Low CK, Alexander WD, McLarty DG, Kalk WJ. The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. J Clin Pharmac 1980;9:137-143 (Pubitemid 10183134)
40. Okuno A, Taguchi T, Inyaku F, Yano K, Suzuki Y. Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease after a single oral dose. Pediatr Pharmacol (New York) 1983;3:43-47
41. Kampmann JP, Mortensen HB, Bach B, Waldorff S, Kristensen MB, Hansen JM. Kinetics of propylthiouracil in the elderly. Acta Med Scand 1979;624:93-98
42. Karras S, Tzotzas T, Krassas GE. Antithyroid drugs used in the treatment of hyperthyroidism during breastfeeding: an update and new perspectives. Hormones (Athens) 2009;8:254-257
43. Williams RH, Kay GA, Jandorf BJ. Thiouracil. Its absorption, distribution, and excretion. J Clin Invest 1944;23:613-627
44. Chesley LC. Observations on the absorption, apparent volume of distribution and excretion of thiourea. J Biol Clin 1944;23:856-858
45. Kampmann JP, Johansen K, Hansen JM, Helweg J. Propylthiouracil in human milk. Revision of a dogma. Lancet 1980;1:736-737
46. Low LC, Lang J, Alexander WD. Excretion of carbimazole and propylthiouracil in breast milk. Lancet 1979;2:1011
47. Johansen K, Andersen AN, Kampmann JP, Mølholm Hansen JM, Mortensen HB. Excretion of methimazole in human milk. Eur J Clin Pharmacol 1982;23:339-341
48. Cooper DS, Bode HH, Nath B, Saxe V, Maloof F, Ridgway EC. Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab 1984;58:473-479 (Pubitemid 14166153)
49. Lamberg BA, Ikonen E, Osterlund K, Teramo K, Pekonen F, Peltola J, Välimäki M. Antithyroid treatment of maternal hyperthyroidism during lactation. Clin Endocrinol (Oxf) 1984;21:81-87 (Pubitemid 14086221)
50. Momotani N, Yamashita R, Yoshimoto M, Noh J, Ishikawa N, Ito K. Recovery from foetal hypothyroidism: evidence for the safety of breast-feeding while taking propylthiouracil. Clin Endocrinol (Oxf) 1989;31:591-595
51. Momotani N, Yamashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf) 2000;53:177-181
52. McDougall IR, Bayer MF. Should a woman taking propylthiouracil breast-feed? Clin Nucl Med 1986;11:249-250
53. Cooper DS. Antithyroid drugs: to breast-feed or not to breast-feed. Am J Obstet Gynecol 1987;157:234-235
54. Goldman JM. Propylthiouracil and breast-feeding. CMAJ 1987;137:701-702
55. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 1989;84:924-936
56. Lee A, Moretti ME, Collantes A, Chong D, Mazzotta P, Koren G, Merchant SS, Ito S. Choice of breastfeeding and physicians' advice: a cohort study of women receiving propylthiouracil. Pediatrics 2000;106(Pt 1):27-30
57. Rylance GW, Woods CG, Donnelly MC, Oliver JS, Alexander WD. Carbimazole and breastfeeding. Lancet 1987;1:928
58. Azizi F. Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast-feeding infants. J Pediatr 1996;128:855-858 (Pubitemid 26181387)
59. Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J Endocrinol Invest 2002;25:493-496
60. Azizi F. Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. J Endocrinol Invest 2003;26:301-304
61. Ordookhani A, Pearce EN, Hedayati M, Mirmiran P, Salimi S, Azizi F, Braverman LE. Assessment of thyroid function and urinary and breast milk iodine concentrations in healthy newborns and their mothers in Tehran. Clin Endocrinol (Oxf) 2007;67:175-179
62. Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab 2000;85:3233-3238
63. Azizi F, Bahrainian M, Khamseh ME, Khoshniat M. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. Pediatr Endocrinol Metab 2003;16:1239-1243
64. Moore FD. Toxic manifestations of thiouracil therapy. JAMA 1946;130:315-319
65. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995;80:1083-1085
66. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-1733
67. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003;37:224-228
68. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993;118:424-428
69. Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001;96:165-169
70. Lian XL, Bai Y, Dai WX, Jin ZM, Zeng ZP, Guo ZS. The clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism. Zhonghua Nei Ke Za Zhi 2004;43:442-446
71. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Hepatic toxicity following treatment for pediatric Graves' disease. Minutes of October 28, 2008 meeting
72. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-1575
73. Rivkees SA, Mattison DR. Propylthiouracil (PTU)-induced liver failure and recommendations for the discontinuation of PTU use in children. Int J Pediatr Endocrinol 2009;2009:132041
74. U.S. Food and Drug Administration. Propylthiouracyl (PTU)-related liver toxicity. April 18, 2009 workshop
75. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010 Jun 23 [epub ahead of print]
76. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN.The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673-674
77. Rivkees SA, Szarfmann A. Dissimilar hepatoxicity profiles of propylthiouracil and methimazole on children. J Clin Endocrinol Metab 2010;95:3260-3267
78. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP, Koutras DA. Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Thyroid 2000;10:527-532 (Pubitemid 30670612)
79. Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995;25:654-658
80. Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004;60:671-675
81. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxf) 2008;47:1515-1520
82. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270-4273
83. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001;86:2354-2359 (Pubitemid 32545676)
84. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A; Endocrine Society Clinical Practice Guideline. Management of thyroid dysfunction during pregnancy and postpartum. J Clin Endocrinol Metab 2007;92 (suppl 8):S1-S47
85. Glatstein MM, Garcia-Bournissen F, Giglio N, Finkelstein Y, Koren G. Pharmacologic treatment of hyperthyroidism during lactation. Can Fam Physician 2009;55:797-798